AIM
ACRS icon

Acrospire Investment Management’s Aclaris Therapeutics ACRS Stock Holding History

Acrospire Investment Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-583
Closed -$17K – 2134
2017
Q1 		$17K Buy
+583
New +$16.8K 0.01% 1683

Other funds holding ACRS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Acrospire Investment Management's ACRS Position: Q2 2017 in Review

Acrospire Investment Management sold out of Aclaris Therapeutics (ACRS) in Q2 2017, closing a stake of 583 shares — an estimated $17K sold.

Acrospire Investment Management first reported a position in ACRS in Q1 2017 and held it in 1 quarter. The position peaked at $17K in Q1 2017. 104 funds tracked by Wall St. Rank hold ACRS as of Q2 2017.

  • Acrospire Investment Management reported no remaining Aclaris Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 583 Aclaris Therapeutics shares in Q2 2017, an estimated $17K.
  • Acrospire Investment Management first reported a position in Aclaris Therapeutics in Q1 2017 and held it in 1 quarter.
  • Acrospire Investment Management's Aclaris Therapeutics position peaked at $17K in Q1 2017.
  • 104 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.